GLP-1 Drugs Reducing Bariatric Surgery Rates
A Wells Fargo report indicates that GLP-1 medications have significantly disrupted the bariatric surgery market, reducing procedures by over 30% as patients opt for this less invasive pharmaceutical alternative for weight management. GLP-1 usage has surged 120% between 2022 and 2024, fundamentally shifting how the healthcare industry approaches weight loss treatment. This trend presents new opportunities for healthcare providers to pivot toward medication management and side effect mitigation services.
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.
Trending